AMG 176, a selective MCL1 inhibitor, is effective in hematological cancer models alone and in combination with established therapies
Publication Year 2018-09-25, Volume 8, Issue #12, Page 1582-1597
Journal Title
Cancer Discovery
Publication Type
Journal Article
The prosurvival BCL-2 family member MCL1 is frequently dysregulated in cancer. To overcome the significant challenges associated with inhibition of MCL1 protein-protein interactions, we rigorously applied small-molecule conformational restriction, which culminated in the discovery of AMG 176, the first selective MCL1 inhibitor to be studied in humans. We demonstrate that MCL1 inhibition induces a rapid and committed step towards apoptosis in subsets of hematological cancer cell lines, tumor xenograft models, and primary patient samples. With the use of a human MCL1 knock-in mouse, we demonstrate that MCL1 inhibition at active doses of AMG 176 is tolerated and correlates with clear pharmacodynamic effects, demonstrated by reductions in B-cells, monocytes and neutrophils. Furthermore, the combination of AMG 176 and venetoclax is synergistic in AML tumor models and in primary patient samples at tolerated doses. These results highlight the therapeutic promise of AMG 176 and the potential for combinations with other BH3 mimetics.
WEHI Research Division(s)
Cancer And Haematology
PubMed ID
NHMRC Grants
NHMRC/1057742 NHMRC/1016647 NHMRC/1016701
Rights Notice
Refer to copyright notice on published article.

Creation Date: 2018-10-11 04:23:14
Last Modified: 2020-06-17 09:17:12
An error has occurred. This application may no longer respond until reloaded. Reload 🗙